Search Results
Mar 25, 2026, 08:17 ET Volition Announces Detection of Over 95% of Early-Stage Cancers
HENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of
More news about: VolitionRx Limited
Mar 18, 2026, 08:17 ET Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived
More news about: VolitionRx Limited
Mar 06, 2026, 08:10 ET Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay
More news about: VolitionRx Limited
Feb 25, 2026, 08:10 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress
More news about: VolitionRx Limited
Feb 10, 2026, 08:07 ET Volition Announces the Appointment of New Distributor for Nu.Q® Discover
HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive
More news about: VolitionRx Limited
Feb 09, 2026, 17:20 ET VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
HENDERSON, Nev., Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it received a notice (the "Notice") from
More news about: VolitionRx Limited
Feb 04, 2026, 08:45 ET Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF)
More news about: VolitionRx Limited
Jan 30, 2026, 08:50 ET VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government
More news about: VolitionRx Limited
Jan 27, 2026, 08:00 ET Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the
More news about: VolitionRx Limited
Jan 20, 2026, 08:25 ET Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test
More news about: VolitionRx Limited
Jan 16, 2026, 08:45 ET Volition Sponsors Symposium at Veterinary Meeting and Expo
HENDERSON, Nev., Jan. 16, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the world's leading veterinary education conference,
More news about: VolitionRx Limited
Jan 08, 2026, 09:15 ET VolitionRx Secures $2.0 Million in Funding
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase
More news about: VolitionRx Limited
Jan 08, 2026, 08:45 ET VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline
More news about: VolitionRx Limited
Dec 17, 2025, 08:45 ET Volition Issues Business Review 2025
HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief
More news about: VolitionRx Limited
Dec 11, 2025, 09:00 ET Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "
More news about: VolitionRx Limited
Dec 08, 2025, 09:00 ET Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC)
More news about: VolitionRx Limited
Dec 04, 2025, 09:00 ET VolitionRx Limited annonce l'intégration de son test Nu.Q® NETs en tant que biomarqueur innovant dans l'évaluation en vie réelle menée en France sur la détection précoce du sepsis
HENDERSON, Nev., 4 décembre 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), une société multinationale spécialisée dans l'épigénétique, annonce aujourd'hui l'intégration de son test Nu.Q® NETs H3.1 dans « DETECSEPS
More news about: VolitionRx Limited
Dec 04, 2025, 09:00 ET VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation
More news about: VolitionRx Limited
Nov 25, 2025, 08:45 ET VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers,
More news about: VolitionRx Limited
Nov 25, 2025, 08:45 ET VolitionRx Limited annonce le premier contrat de vente des tests Nu.Q® Cancer pour la validation clinique en vue d'une utilisation pratique de soins courants
HENDERSON, Nev., 25 novembre 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (« Volition »), une société multinationale spécialisée dans l'épigénétique, annonce aujourd'hui le premier contrat de vente de ses tests Nu.Q® Cancer
More news about: VolitionRx Limited
Nov 13, 2025, 16:10 ET VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30,
More news about: VolitionRx Limited
Nov 10, 2025, 08:45 ET VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and
More news about: VolitionRx Limited
Oct 17, 2025, 08:00 ET Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
HENDERSON, Nev., Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate social responsibility strategy announces
More news about: VolitionRx Limited
Oct 10, 2025, 08:30 ET VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares
More news about: VolitionRx Limited
Oct 09, 2025, 16:05 ET VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public
More news about: VolitionRx Limited